Nerdwallet Inc vs Zoetis Inc — how do they compare? Nerdwallet Inc trades at $9.41 (market cap $610.79M), while Zoetis Inc trades at $73.51 (market cap $30.40B). The key difference: Zoetis Inc is far larger — about 49.8× Nerdwallet Inc's market cap, and Zoetis Inc pays a 2.88% dividend while Nerdwallet Inc pays none. Which is the better fit depends on your goals.
| NRDS | ZTS | |
|---|---|---|
Market Cap | $610.79M | $30.40B |
Sector | Financials | Health |
52-Week High | $15.93 | $150.61 |
52-Week Low | $7.58 | $71.91 |
Enterprise Value | $525.09M | $37.96B |
Dividend Yield | — | 2.88% |
Signals from Pluang's Aura AI — not financial advice
NRDS trades at $9.56, down 3.24% amid bearish technical signals, though fundamentals show strong improvement with revenue growing from $539M in 2022 to $837M in 2025 and net income turning positive. The stock appears undervalued with a P/E of 10.62 and P/S of 0.79, while analyst sentiment remains positive with 4 out of 6 ratings being Buy. Recent Q2 2026 earnings missed expectations but management highlights an inflection point in business operations.
The outlook is mixed: strong profitability metrics (93.5% gross margin, 18.16% ROE) and analyst price targets suggesting 27.9% upside support bullish case, but technical weakness and competitive pressures in credit card/search segments pose near-term risks. Execution on Q3 guidance and sustained cash flow generation will be critical for stock performance.
Zoetis (ZTS) trades at $73.60, down 2.92% amid bearish technical signals and mixed earnings. The stock faces pressure from weakening U.S. companion animal sales and competitive headwinds, though profitability remains strong with 71.67% gross margins and 27.69% net income margin. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a guidance cut. Analyst consensus is divided with 45% Buy ratings and a $93.40 price target, suggesting 27% upside from current levels.
The outlook balances valuation appeal (P/E of 12) against near-term operational challenges. Investment opportunity lies in market dominance and robust cash flow generation, while risks include sustained pet health demand softness and competitive pricing pressure. The stock trades near support at $73, with institutional sentiment mixed amid recent portfolio adjustments.
Trailing returns across standard periods
Latest headlines on both assets
Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.
Read more on NRDS →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →